These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 21940589)

  • 1. Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging.
    Hamilton BE; Nesbit GM; Dosa E; Gahramanov S; Rooney B; Nesbit EG; Raines J; Neuwelt EA
    AJR Am J Roentgenol; 2011 Oct; 197(4):981-8. PubMed ID: 21940589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.
    Gahramanov S; Raslan AM; Muldoon LL; Hamilton BE; Rooney WD; Varallyay CG; Njus JM; Haluska M; Neuwelt EA
    Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):514-23. PubMed ID: 20395065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Magnetic resonance imaging of intracranial tumors: intra-patient comparison of gadoteridol and ferumoxytol.
    Dósa E; Guillaume DJ; Haluska M; Lacy CA; Hamilton BE; Njus JM; Rooney WD; Kraemer DF; Muldoon LL; Neuwelt EA
    Neuro Oncol; 2011 Feb; 13(2):251-60. PubMed ID: 21163809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative comparison of delayed ferumoxytol T
    Horváth A; Varallyay CG; Schwartz D; Toth GB; Netto JP; Barajas R; Várallyay P; Szidonya L; Firkins J; Youngers E; Fu R; Ambady P; Bogner P; Neuwelt EA
    Magn Reson Med; 2018 Jul; 80(1):224-230. PubMed ID: 29205477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival.
    Gahramanov S; Muldoon LL; Varallyay CG; Li X; Kraemer DF; Fu R; Hamilton BE; Rooney WD; Neuwelt EA
    Radiology; 2013 Mar; 266(3):842-52. PubMed ID: 23204544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study.
    Neuwelt EA; Várallyay CG; Manninger S; Solymosi D; Haluska M; Hunt MA; Nesbit G; Stevens A; Jerosch-Herold M; Jacobs PM; Hoffman JM
    Neurosurgery; 2007 Apr; 60(4):601-11; discussion 611-2. PubMed ID: 17415196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebral blood volume mapping with ferumoxytol in dynamic susceptibility contrast perfusion MRI: Comparison to standard of care.
    Varallyay CG; Nesbit E; Horvath A; Varallyay P; Fu R; Gahramanov S; Muldoon LL; Li X; Rooney WD; Neuwelt EA
    J Magn Reson Imaging; 2018 Aug; 48(2):441-448. PubMed ID: 29314418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of ferumoxytol- and gadolinium chelate-enhanced MRI for assessment of sarcomas in children and adolescents.
    Siedek F; Muehe AM; Theruvath AJ; Avedian R; Pribnow A; Spunt SL; Liang T; Farrell C; Daldrup-Link HE
    Eur Radiol; 2020 Mar; 30(3):1790-1803. PubMed ID: 31844962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of ferumoxytol with gadolinium as contrast agents for the diagnostic magnetic resonance imaging of osteomyelitis.
    Langsjoen J; Neuwelt A; Eberhardt S; Mlady G; Shukla U; Murali S; Pizanis C; Sillerud LO
    Magn Reson Imaging; 2020 Sep; 71():45-54. PubMed ID: 32439428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors.
    Thompson EM; Guillaume DJ; Dósa E; Li X; Nazemi KJ; Gahramanov S; Hamilton BE; Neuwelt EA
    J Neurooncol; 2012 Aug; 109(1):105-14. PubMed ID: 22528798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ferumoxytol-Enhanced MRI Is Not Inferior to Gadolinium-Enhanced MRI in Detecting Intracranial Metastatic Disease and Metastasis Size.
    Hamilton BE; Barajas R; Nesbit GM; Fu R; Ambady P; Taylor M; Neuwelt EA
    AJR Am J Roentgenol; 2020 Dec; 215(6):1436-1442. PubMed ID: 33052739
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of Three Ultrasmall, Superparamagnetic Iron Oxide Nanoparticles for MRI at 3.0 T.
    Colbert CM; Ming Z; Pogosyan A; Finn JP; Nguyen KL
    J Magn Reson Imaging; 2023 Jun; 57(6):1819-1829. PubMed ID: 36250695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression.
    Barajas RF; Hamilton BE; Schwartz D; McConnell HL; Pettersson DR; Horvath A; Szidonya L; Varallyay CG; Firkins J; Jaboin JJ; Kubicky CD; Raslan AM; Dogan A; Cetas JS; Ciporen J; Han SJ; Ambady P; Muldoon LL; Woltjer R; Rooney WD; Neuwelt EA
    Neuro Oncol; 2019 Mar; 21(4):517-526. PubMed ID: 30277536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidental ferumoxytol artifacts in clinical brain MR imaging.
    Bowser BA; Campeau NG; Carr CM; Diehn FE; McDonald JS; Miller GM; Kaufmann TJ
    Neuroradiology; 2016 Nov; 58(11):1087-1091. PubMed ID: 27704163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging applications for ferumoxytol as a contrast agent in MRI.
    Bashir MR; Bhatti L; Marin D; Nelson RC
    J Magn Reson Imaging; 2015 Apr; 41(4):884-98. PubMed ID: 24974785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of ultrasmall particles of iron oxide (USPIO)-enhanced T2-weighted, conventional T2-weighted, and gadolinium-enhanced T1-weighted MR images in rats with experimental autoimmune encephalomyelitis.
    Dousset V; Ballarino L; Delalande C; Coussemacq M; Canioni P; Petry KG; Caillé JM
    AJNR Am J Neuroradiol; 1999 Feb; 20(2):223-7. PubMed ID: 10094342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors.
    Varallyay P; Nesbit G; Muldoon LL; Nixon RR; Delashaw J; Cohen JI; Petrillo A; Rink D; Neuwelt EA
    AJNR Am J Neuroradiol; 2002 Apr; 23(4):510-9. PubMed ID: 11950637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal metastasis. Detection and characterization on enhanced magnetic resonance imaging using an animal model.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1997 Apr; 32(4):212-7. PubMed ID: 9101356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delineation of gliomas with various doses of MR contrast material.
    Yuh WT; Nguyen HD; Tali ET; Mayr NA; Fisher DJ; Atlas SW; Carvlin MC; Drayer BP; Pollei SR; Runge VM
    AJNR Am J Neuroradiol; 1994 May; 15(5):983-9. PubMed ID: 8059672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ferumoxytol Does Not Impact Standardized Uptake Values on PET/MR Scans.
    Muehe AM; Yerneni K; Theruvath AJ; Thakor AS; Pribnow A; Avedian R; Steffner R; Rosenberg J; Hawk KE; Daldrup-Link HE
    Mol Imaging Biol; 2020 Jun; 22(3):722-729. PubMed ID: 31325083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.